NCT05120960 2024-04-17A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsM.D. Anderson Cancer CenterPhase 1 Withdrawn
NCT05693090 2023-03-06Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerKura Oncology, Inc.Phase 1 Withdrawn